Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. Along with Zolgensma – which made its debut in 2019 – Biogen has had ...
Zacks.com on MSN10d
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 BillionNovartis NVS has entered into a global license and collaboration agreement with PTC Therapeutics PTCT for the latter’s ...
Hosted on MSN9mon
Novartis presents new data on safety and efficacy of key therapy to spinal muscular atrophyNovartis on Monday presented new data that continue to support the clinical benefits of Zolgensma (onasemnogene abeparvovec) which is the only one-time gene therapy for the treatment of spinal ...
Novartis—which markets the gene therapy Zolgensma for spinal muscular atrophy—has been working in neuroscience for “many years,” the CEO pointed out in his presentation, namechecking ...
In a meta-analysis of 57 studies, Zolgensma achieved a 95% survival rate and reduced the number of patients requiring ...
Zolgensma is a gene therapy that treats children under two years old with spinal muscular atrophy (SMA). It was the first gene therapy approved by the FDA to treat a disease. Novartis priced an ...
Zolgensma, Kisqali and Leqvio should fuel growth through 2030 and beyond. NVS boasts a Value Style Score of A and VGM Score of B, and holds a Zacks Rank #2 (Buy) rating. Shares of Novartis are ...
Novartis' drug segment is poised for steady ... (hidradenitis suppurativa in 2023), spinal muscular atrophy drug Zolgensma (intrathecal data in 2024), and cardiovascular drug Leqvio (outcomes ...
Zolgensma is a gene therapy that treats children under two years old with spinal muscular atrophy (SMA). It was the first gene therapy approved by the FDA to treat a disease. Novartis priced an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback